Correction to J&J Actelion Story

Features Dow Jones Newswires

"J&J Plans to Add Drug Discovery and Early Research to Actelion Unit," at 1:05 p.m. EDT, incorrectly stated that J&J's initial stake would be 16% in the final paragraph. A J&J subsidiary initially will hold a 9.9% stake in the new company, with an option to increase this to 32% in the future. (June 14)

Continue Reading Below

(END) Dow Jones Newswires

June 14, 2017 15:36 ET (19:36 GMT)